CD99 and neoplasm: By developing function‐associated single‐cell RNA sequencing (FascRNA‐seq) platform, researchers utilized 171 individual primary lung cancer organoids (pLCOs) from seven patients, thus dissected the tumor immunity involving CD8+ T cells and macrophages under anti‐PD‐1 treatment, and identified CD99 as a potential regulator of T cell activity.